John F Dillon
Biographic Data
| ID | 1737165 |
|---|---|
| NAME | John F Dillon |
| GIVEN NAMES | John F |
| FAMILY NAME | Dillon |
| SIGNATURE | DILLON J F |
| AFFILIATIONS | Ninewells Hospital |
| VERIFIED | No |
| TOTAL WORKS | 7 |
| TOTAL CITATIONS | 4 |
| WORKS AS AUTHOR | 7 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 1887 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 1 |
Universal Barriers and Facilitators to Systemic Hepatitis C Care
Scaling up hepatitis C virus (HCV) testing and treatment for people who inject drugs (PWID) is essential to achieve HCV elimination. We report a retrospective systems‐informed qualitative process evaluation of HCV care across multiple community‐based settings in a region in Scotland, UK. Using secondary data from 71 semi‐structured interviews with HCV service providers ( n = 40) and service users ( n = 31) from across the whole system, we identif…
Eradicating hepatitis C
Targeting PWID populations with screening at needle exchange services is a highly cost-effective strategy for reaching undiagnosed HCV patients. When applying realistic discounts to list prices of drug treatments, all three strategies were highly cost-effective from a UK NHS perspective. All of these strategies have the potential to make a cost-effective contribution to the eradication of HCV by 2030
Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Hepatitis C virus treatment for prevention among people who inject drugs
UNLABELLED: Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake is low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of …
Does geographic access to primary healthcare influence the detection of hepatitis C
Our Legal Chaos
Our Legal Chaos
Does geographic access to primary healthcare influence the detection of hepatitis C
Hepatitis C virus treatment for prevention among people who inject drugs
UNLABELLED: Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake is low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of …
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs
Eradicating hepatitis C
Targeting PWID populations with screening at needle exchange services is a highly cost-effective strategy for reaching undiagnosed HCV patients. When applying realistic discounts to list prices of drug treatments, all three strategies were highly cost-effective from a UK NHS perspective. All of these strategies have the potential to make a cost-effective contribution to the eradication of HCV by 2030
Universal Barriers and Facilitators to Systemic Hepatitis C Care
Scaling up hepatitis C virus (HCV) testing and treatment for people who inject drugs (PWID) is essential to achieve HCV elimination. We report a retrospective systems‐informed qualitative process evaluation of HCV care across multiple community‐based settings in a region in Scotland, UK. Using secondary data from 71 semi‐structured interviews with HCV service providers ( n = 40) and service users ( n = 31) from across the whole system, we identif…
Hepatitis C virus research (5 works) · HIV, Drug Use, Sexual Risk (5 works) · Hepatitis C (4 works) · Medicine (4 works) · Diabetes Management and Education (2 works) · Environmental health (2 works) · Family medicine (2 works) · Hepatitis C virus (2 works) · Intensive care medicine (2 works) · Internal Medicine (2 works)